Dosing Guidelines and Dosage Adjustment Strategies for Sotoraxib (AMG510)

Sotorasib, also known asAMG510 or Sotorasib, is an innovative drug targeting the KRAS G12C mutation. It provides a new treatment option for patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). This drug can precisely lock and inhibit the activity of KRAS G12C protein, thereby curbing the proliferation and spread of tumor cells.

In order to ensure that sotoraxib can maintain a stable and effective drug concentration in the body to achieve the best therapeutic effect, doctors recommend a daily dosage of 960mg, taken once a day. Patients can choose to take three 320 mg tablets, or eight 120 mg tablets. It is important that patients strictly follow their doctor's instructions and take their medications according to their doctor's specific instructions.

For some patients, swallowing solid tablets may be difficult. In this case, you can disperse the sotorazeb tablets in 120 mL of non-carbonated, room temperature water, but be sure not to crush the tablets or use any other type of liquid. Patients need to gently stir or swirl the cup for about 3 minutes until the tablets are completely dispersed. Patients are advised to finish drinking within the next 2 hours. At this point, the mixture should appear pale to bright yellow. It is important to note that patients should not chew the tablets but drink the mixture directly. After drinking, the patient needs to rinse the container with an additional 120 mL of water and drink to ensure complete intake of the drug. If the mixture has been sitting for a while, stir it again before drinking to make sure the tablets are completely dispersed.

During the process of taking sotorasib, if the patient experiences adverse reactions, the doctor will adjust the drug dosage according to the situation. Usually, the first dose will be reduced to 480mg, and if adverse reactions persist, it will be further reduced to 240mg. It is worth noting that the dose can be reduced up to two times. If the patient is unable to tolerate the minimum daily dose of 240 mg, sotoraxib should be discontinued.

If the patient develops adverse reactions such as hepatotoxicity, interstitial lung disease (ILD)/pneumonitis, it is generally recommended to stop using sotoraxib. If the patient has appropriate supportive treatment for adverse reactions such as nausea, vomiting, and diarrhea, sotorasiib should be withheld until recovery to ≤ Grade 1 or baseline, and sotorasiib should be resumed at the next lower dose level. Avoid concomitant use of proton pump inhibitors (PPIs) and H2 sotoracib receptor antagonists. If treatment with acid-reducing agents cannot be avoided, it is recommended to take sotoracib 4 hours before or 10 hours after the use of topical antacids.

Additionally, if the patient misses more than With a 6-hour medication time, it is recommended to skip this dose and take the next dose as prescribed the next day. Likewise, if a patient vomits after taking a dose, the dose should be skipped and resumed the next day. During the entire treatment process, patients should pay close attention to their own body reactions and communicate with their doctors in a timely manner so that the doctors can adjust the drug dosage according to the actual situation to ensure the safety and effectiveness of the treatment.